What’s the current market cap for Apogee Therapeutics stock?

Apogee Therapeutics (APGE) has a market cap of $6.2bn as of June 09, 2026.

What is the P/E ratio for Apogee Therapeutics stock?

The price to earnings (P/E) ratio for Apogee Therapeutics (APGE) stock is 0 as of June 09, 2026.

Does Apogee Therapeutics stock pay dividends?

No, Apogee Therapeutics (APGE) stock does not pay dividends to its shareholders as of June 09, 2026.

When is the next Apogee Therapeutics dividend payment date?

Apogee Therapeutics (APGE) stock does not pay dividends to its shareholders.

What is the beta indicator for Apogee Therapeutics?

Apogee Therapeutics (APGE) has a beta rating of 0.69. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Apogee Therapeutics stock | $APGE Share Price

13:30

15:10

16:45

18:25

20:00

About Apogee Therapeutics

Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Ticker

$APGE

Sector

Health

Primary listing

NASDAQ

Employees

261

Headquarters

Waltham, United States

Website

www.apogeetherapeutics.com

APGE Metrics

BasicAdvanced

$6.2bn

-$4.32

0.69

Bulls say / Bears say

52-week data from the Phase 2 APEX Part A trial in atopic dermatitis showed 75–85 percent EASI-75 response maintenance and improved efficacy across all lesion and itch endpoints, highlighting zumilokibart’s potential best-in-class profile (Reuters)

Apogee raised around $403 million in gross proceeds through an upsized public equity offering and reported a $1.3 billion cash position, extending its cash runway into 2029 to support planned BLA filings and the launch of Phase 3 trials (Nasdaq)

Interim Phase 1b asthma results showed robust FeNO suppression through 16 weeks (and up to 32 weeks in some patients) with a favorable safety profile, supporting the pipeline-in-a-product strategy for respiratory indications (Reuters)

Net loss widened to $74.1 million in Q1 2026 from $55.3 million a year earlier, driven by higher R&D and G&A expenses, highlighting increased cash burn risks (TradingView)

Apogee remains pre-commercial with no product revenue and no approved therapies, making its valuation entirely reliant on future clinical trial success (TradingView)

With a market valuation of about $4.55 billion despite not having commercialized products, several analysts have flagged possible overvaluation and downgraded the stock, reflecting valuation concerns (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $APGE

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Net loss widened to $74.1 million in Q1 2026 from $55.3 million a year earlier, driven by higher R&D and G&A expenses, highlighting increased cash burn risks (TradingView)

Apogee remains pre-commercial with no product revenue and no approved therapies, making its valuation entirely reliant on future clinical trial success (TradingView)

Data summarised monthly by Lightyear AI. Last updated on 24 May 2026.